Colgate-Palmolive Company (CL) Q4 2024 earnings summary

Executive summary

• Achieved record net sales over $20 billion in 2024, with 7.4% organic growth and all divisions posting positive volume growth, surpassing strategic plan targets a year early.

• Delivered balanced pricing and volume growth, with increased advertising spend and innovation driving improved brand health and global market share gains.

• Base Business EPS rose 11% year-over-year; GAAP EPS up 27% to $3.51, with record operating and free cash flow and $3.4 billion returned to shareholders, up 26% from 2023.

• Expanded gross and operating margins despite significant FX headwinds and higher investment in advertising and capabilities.

• Entering 2025 with confidence in strategy, focusing on innovation, data, analytics, and AI to sustain growth and flexibility in the P&L.

Financial highlights

• Net sales reached over $20 billion in 2024, with 7.4% organic growth and high single-digit EPS growth, both ahead of initial guidance.

• Gross profit margin expanded 240 basis points for the year to 60.5%, with Q4 margin up 70 basis points to 60.3%.

• Operating cash flow hit a record $4.1 billion; free cash flow before dividends was $3,546 million.

• Advertising spend increased 15% in 2024, supporting brand health and innovation.

• Return on invested capital reached 35.9%, up 760 basis points year-over-year.

Outlook and guidance

• 2025 guidance calls for 3%-5% organic sales growth, with net sales roughly flat due to a mid-single-digit negative FX impact and the planned exit from private label pet nutrition.

• EPS expected to grow low to mid-single digits, with continued FX headwinds anticipated.

• Gross margin expansion expected, driven by mix, productivity, and innovation, with advertising spend flat to slightly up as a percent of sales.

• Raw and packaging material costs anticipated to increase modestly due to higher commodity prices and FX.

• Shift from pricing-driven to volume-driven growth, with broad-based volume contributions across regions.